Article Text

Download PDFPDF
Letter
Switching from natalizumab to alemtuzumab in patients with relapsing multiple sclerosis

Statistics from Altmetric.com

Footnotes

  • Contributors NJ and WJB planned the study. NJ and AC were involved in data acquisition. NJ completed data analysis and drafted the manuscript. WJB provided key edits to the manuscript. The final manuscript was reviewed and edited by AC, WJB and JC. The guarantor for the content of the manuscript is JC.

  • Competing interests WJB has received speaker honoraria for educational activities for Merck Serono, Roche and Sanofi Genzyme. JC has received support from the Efficacy and Mechanism Evaluation Programme and Health Technology Assessment Programme (NIHR); UK Multiple Sclerosis Society and National Multiple Sclerosis Society; National Institute for Health Research University College London Hospitals (NIHR-UCLH) Biomedical Research Centre (BRC) and University College London. In the last three years, he has been a local principal investigator for trials in multiple sclerosis funded by: Receptos, Novartis and Biogen Idec, and has received an investigator grant from Novartis outside this work. He has taken part in Advisory Boards/consultancy for Apitope, Roche, Merck, MedDay, Biogen and Celgene.

  • Patient consent for publication Not required.

  • Ethics approval The study was approved by the Queen Square Quality and Safety Committee, National Hospital for Neurology and Neurosurgery.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.